<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196531</url>
  </required_header>
  <id_info>
    <org_study_id>CR108328</org_study_id>
    <secondary_id>1754415ALY1002</secondary_id>
    <nct_id>NCT03196531</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets</brief_title>
  <official_title>A Single-Dose, Randomized, Open-Label, Two-Treatment, Four-Period, Crossover Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Subjects Compared With Clarityne Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xian-Janssen Pharmaceutical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xian-Janssen Pharmaceutical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence of Xisimin (loratadine) compared
      with Clarityne in healthy participants receiving a single dose of 10 milligram (mg) under
      fasting condition as part of Cohort 1 and under fed condition as part of Cohort 2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2017</start_date>
  <completion_date type="Actual">March 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Loratadine</measure>
    <time_frame>Cohort 1 and Cohort 2: Predose, 0.25 hour (h), 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h postdose</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]) for Loratadine</measure>
    <time_frame>Cohort 1 and Cohort 2: Predose, 0.25 hour (h), 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h postdose</time_frame>
    <description>The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) for Loratadine</measure>
    <time_frame>Cohort 1 and Cohort 2: Predose, 0.25 hour (h), 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h postdose</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>From Screening to Day 5 of Period 4 (Approximately 33 days)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Sequence 1 (ABAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Sequence 2 (BABA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Sequence 1 (ABAB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Sequence 2 (BABA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine (Xisimin [Test Treatment])</intervention_name>
    <description>Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.</description>
    <arm_group_label>Cohort 1: Sequence 1 (ABAB)</arm_group_label>
    <arm_group_label>Cohort 1: Sequence 2 (BABA)</arm_group_label>
    <arm_group_label>Cohort 2: Sequence 1 (ABAB)</arm_group_label>
    <arm_group_label>Cohort 2: Sequence 2 (BABA)</arm_group_label>
    <other_name>JNJ-1754415-AAA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine (Clarityne [Reference Treatment])</intervention_name>
    <description>Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.</description>
    <arm_group_label>Cohort 1: Sequence 1 (ABAB)</arm_group_label>
    <arm_group_label>Cohort 1: Sequence 2 (BABA)</arm_group_label>
    <arm_group_label>Cohort 2: Sequence 1 (ABAB)</arm_group_label>
    <arm_group_label>Cohort 2: Sequence 2 (BABA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If a woman, must be surgically sterile, abstinent, or, if sexually active, be
             practicing an effective method of birth control (for example, prescription oral
             contraceptives, contraceptive injections, intrauterine device, double-barrier method,
             contraceptive patch, male partner sterilization) before entry, throughout the study,
             and for 1 month after the last dose of study drug

          -  If a woman, must have a negative serum pregnancy test at screening and a negative
             serum pregnancy test on Day -1 of each treatment period

          -  If a woman, must agree not to donate eggs (ova, oocytes) for the purposes of assisted
             reproduction during the study and for 2 months after receiving the last dose of study
             drug

          -  If a man who is sexually active with a woman of childbearing potential and has not had
             a vasectomy, must agree to use an adequate contraception method as deemed appropriate
             by the investigator (for example, vasectomy, double-barrier, partner using effective
             contraception) and to not donate sperm during the study and for 3 months after
             receiving the last dose of study drug. Must agree to continue using an appropriate
             method of birth control during the study and for 3 months after the last dose of study
             drug

          -  Body mass index (BMI, weight [kilogram]/height^2 [meter^2] {[kg]/height2 [m]2})
             between 19.0 and 26.0 kilogram per meter square (kg/m2) (inclusive); body weight of
             male participants not less than 50 kilogram (kg) and body weight of female
             participants not less than 45 kg

        Exclusion Criteria:

          -  History of or current clinically significant medical illness including (but not
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,
             coagulation disorders (including any abnormal bleeding or blood dyscrasias),
             gastrointestinal disease, lipid abnormalities, significant pulmonary disease,
             including bronchospastic respiratory disease, diabetes mellitus, renal or hepatic
             insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any
             other illness that the investigator considers should exclude the participant or that
             could interfere with the interpretation of the study results

          -  Clinically significant abnormal values for hematology, clinical chemistry, urinalysis,
             or 12-lead electrocardiogram (ECG) at screening as deemed appropriate by the
             investigator

          -  Clinically significant abnormal physical examination, or vital signs at screening or
             on Day -1 of each treatment period as deemed appropriate by the investigator

          -  Use of any prescription or Over-the-counter (OTC) drug (including vitamins and
             botanical supplements such as hypericum perforatum [St. John's wort]), except for oral
             contraceptives, within 14 days prior to scheduled administration of the first dose of
             study drug

          -  Positive test for human immunodeficiency virus (HIV) antibodies, hepatitis B surface
             antigen (HBsAg), hepatitis C antibodies or syphilis serum test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xian-Janssen Pharmaceutical Ltd., China Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Xian-Janssen Pharmaceutical Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

